However, several solute carriers (SLCs) that fuel cell metabolism have associated clinical pharmacological inhibitors that are used to treat a variety of medical conditions, such as diabetes (SLC5A2/SGLT2), major depressive and other psychological conditions (selective serotonin reuptake inhibitors; SLC6A4/hSERT), and hypertension and edema (SLC12A1/NKC22; SLC12A3/NCC) (21). This evidence concerns the gene SLC12A1 and hypertensive disorder.